Highlights

  • Revenue climbed 14% to $2.31 billion, supported by strong growth in hospital and homecare product sales.
  • Net profit surged 24% to $468.5 million, reflecting improved margins and strong global Demand across therapies.
  • Dividend increased 22% to 52.0 cents per share, highlighting management’s confidence in Earnings momentum.

Overview

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH) delivered a strong financial performance for FY26, reporting double-digit growth in revenue, profit, and dividends as demand remained robust across its hospital and homecare businesses. Total Operating Revenue rose to $2.31 billion, while net profit after tax climbed to $468.5 million, supported by improved gross margins and solid consumables growth globally. The hospital segment was the standout performer, benefiting from increased adoption of respiratory and acute care therapies, while homecare sales also expanded on the back of continued demand for sleep apnea products. The company also lifted Shareholder returns through a higher dividend and maintained heavy Investment in innovation, allocating $235.5 million to Research and Development. Looking ahead, management expects continued growth in FY27 despite Tariff and geopolitical cost pressures.

Did Fisher & Paykel’s Hospital Business Become the Biggest Growth Driver in FY26?

Fisher & Paykel Healthcare’s hospital division was the biggest contributor to FY26 growth, with revenue rising 18% to $1.51 billion. The segment, which includes respiratory, acute, and surgical care products, saw strong global demand across its therapy portfolio. Hospital consumables revenue also posted double-digit gains, showing continued adoption of the company’s clinical solutions despite softer seasonal respiratory illness admissions in major markets such as the United States. Management said the performance highlights how changing clinical practices are becoming a structural growth driver for the business. The strong momentum in hospital products also helped offset external pressures such as tariffs, reinforcing Fisher & Paykel’s ability to deliver stable earnings growth from its core healthcare operations.

Is Fisher & Paykel’s FY27 Outlook Signaling More Growth Ahead?

Management has guided for another year of growth in FY27, forecasting operating revenue in the range of $2.45 billion to $2.57 billion and net profit after tax between $500 million and $550 million. The company expects gross margins to improve further, although its outlook includes some cost pressure from US tariffs and geopolitical disruption linked to the Middle East conflict. Fisher & Paykel is also continuing to invest in long-term expansion, progressing construction of its fifth East Tāmaki Facility while maintaining significant research and development spending. With product innovation, growing patient adoption, and improving margins supporting performance, the company appears well positioned to sustain earnings momentum in the year ahead.